WO2004002425A3 - Methodes permettant d'ameliorer l'acceptation d'une greffe par depletion des cellules souches hematopoietiques - Google Patents

Methodes permettant d'ameliorer l'acceptation d'une greffe par depletion des cellules souches hematopoietiques Download PDF

Info

Publication number
WO2004002425A3
WO2004002425A3 PCT/US2003/020520 US0320520W WO2004002425A3 WO 2004002425 A3 WO2004002425 A3 WO 2004002425A3 US 0320520 W US0320520 W US 0320520W WO 2004002425 A3 WO2004002425 A3 WO 2004002425A3
Authority
WO
WIPO (PCT)
Prior art keywords
stem cells
hematopoietic stem
depletion
depleting
inactivating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/020520
Other languages
English (en)
Other versions
WO2004002425A2 (fr
Inventor
Julian D Down
Mary E White-Scharf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biotransplant Inc
Original Assignee
Biotransplant Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotransplant Inc filed Critical Biotransplant Inc
Priority to AU2003245752A priority Critical patent/AU2003245752A1/en
Publication of WO2004002425A2 publication Critical patent/WO2004002425A2/fr
Publication of WO2004002425A3 publication Critical patent/WO2004002425A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des compositions thérapeutiques et des méthodes qui permettent de moduler le système immunitaire pour améliorer l'acceptation d'une greffe et pour traiter une malignité hématologique en l'absence de thérapies myéloablatives. La méthodologie décrite comprend une étape qui consiste à appauvrir et/ou à inactiver les cellules souches hématopoïétiques du destinataire au moyen d'une composition thérapeutique comprenant au moins un anticorps spécifique pour appauvrir et/ou inactiver les cellules souches hématopoïétiques tout en préservant les cellules sanguines matures, de préférence l'anticorps appauvrit sélectivement et/ou inactive les cellules souches hématopoïétiques primitives. La composition thérapeutique est de préférence administrée avant l'administration de moelle osseuse, de cellules souches hématopoïétiques périphériques mobilisées ou de leucocytes du donneur.
PCT/US2003/020520 2002-06-28 2003-06-27 Methodes permettant d'ameliorer l'acceptation d'une greffe par depletion des cellules souches hematopoietiques Ceased WO2004002425A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003245752A AU2003245752A1 (en) 2002-06-28 2003-06-27 Process for promoting graft acceptance by depletion of hematopoietic stem cells

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US39259002P 2002-06-28 2002-06-28
US60/392,590 2002-06-28
US35770603A 2003-02-04 2003-02-04
US10/357,706 2003-02-04

Publications (2)

Publication Number Publication Date
WO2004002425A2 WO2004002425A2 (fr) 2004-01-08
WO2004002425A3 true WO2004002425A3 (fr) 2004-08-26

Family

ID=30002887

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/020520 Ceased WO2004002425A2 (fr) 2002-06-28 2003-06-27 Methodes permettant d'ameliorer l'acceptation d'une greffe par depletion des cellules souches hematopoietiques

Country Status (2)

Country Link
AU (1) AU2003245752A1 (fr)
WO (1) WO2004002425A2 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3255061B1 (fr) * 2006-11-03 2021-06-16 The Board of Trustees of the Leland Stanford Junior University Immunodéplétion sélective de niche de cellules souches endogènes pour greffe
EP2349224B1 (fr) 2008-10-10 2017-05-10 Probelte Pharma, S.A. Produit immunostimulant pouvant être administré par voie orale en aquaculture
JP5688734B2 (ja) * 2008-12-12 2015-03-25 国立大学法人 東京大学 移植片対腫瘍効果を保存した免疫学的再構築促進剤または感染症予防剤
US20120189633A1 (en) 2011-01-26 2012-07-26 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies and uses thereof
EP4063391A1 (fr) 2012-07-25 2022-09-28 Celldex Therapeutics, Inc. Anticorps anti-kit et leurs utilisations
WO2015050959A1 (fr) * 2013-10-01 2015-04-09 Yale University Anticorps anti-kits et leurs méthodes d'utilisation
JP6768639B2 (ja) 2014-05-23 2020-10-21 セルデックス セラピューティクス，インコーポレーテッド 好酸球又はマスト細胞関連障害の治療
US20170209447A1 (en) * 2014-08-07 2017-07-27 Nitor Therapeutics Use of PNP Inhibitor to Treat Relapse of Malignancy after Hematopoietic Stem Cell Transplant
ES2945588T3 (es) 2014-08-26 2023-07-04 Univ Leland Stanford Junior Injerto de células madre con una combinación de un agente dirigido a las células madre y modulación de señalización inmunoreguladora
HK1256681A1 (zh) 2015-04-06 2019-10-04 President And Fellows Of Harvard College 用於非清髓性预处理的组合物和方法
ES2894335T5 (es) 2015-08-26 2024-06-27 Univ Leland Stanford Junior Reducción mejorada de células objetivo con bloqueo de CD47 y un agonista coestimulador inmune
US10111966B2 (en) 2016-06-17 2018-10-30 Magenta Therapeutics, Inc. Methods for the depletion of CD117+ cells
CN117653740A (zh) * 2016-12-21 2024-03-08 诺华股份有限公司 用于消融造血干细胞的抗体药物缀合物
IL301075B2 (en) 2017-01-30 2024-05-01 Univ Leland Stanford Junior A genotoxic matching regimen for stem cell transplantation
US12485186B2 (en) 2017-03-31 2025-12-02 The Children's Medical Center Corporation Antibody-mediated conditioning with immunosuppression to enable allogeneic transplantation
WO2019217942A1 (fr) 2018-05-11 2019-11-14 Beam Therapeutics Inc. Procédés de substitution d'acides aminés pathogènes à l'aide de systèmes d'éditeur de bases programmables
UY38265A (es) * 2018-06-20 2020-01-31 Novartis Ag Conjugados anticuerpo droga para ablación de células madre hematopoyéticas
KR20210094609A (ko) 2018-11-28 2021-07-29 포티 세븐, 인코포레이티드 절제 레짐에 대해 저항성인 유전적으로 변형된 hspc
EP3958879A4 (fr) * 2019-04-25 2023-05-10 Actinium Pharmaceuticals, Inc. Compositions et procédés d'immunodéplétion pour le traitement des maladies hématologiques malignes et non malignes
EP4611807A4 (fr) * 2022-11-04 2026-07-29 Univ Leland Stanford Junior Rééquilibrage du système immunitaire par déplétion de cellules souches hématopoïétiques orientées production de myéloïdes

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998007444A1 (fr) * 1996-08-16 1998-02-26 Biotransplant, Inc. ANTICORPS LO-CD2a ET SON UTILISATION POUR INHIBER L'ACTIVATION ET LA PROLIFERATION DE CELLULES T
WO2001025398A2 (fr) * 1999-10-01 2001-04-12 Biotransplant Incorporated Technique permettant d'induire une tolerance fonctionnelle a des produits de transfert genique
WO2001030369A1 (fr) * 1999-10-22 2001-05-03 Biotransplant, Inc. Procede d'induction d'une tolerance immunologique pour des greffons heterologues
WO2001087310A1 (fr) * 2000-05-18 2001-11-22 Biotransplant, Inc. Procede de reduction de la reponse anticorps contre des xenogreffes
WO2002033043A2 (fr) * 2000-10-18 2002-04-25 Coriell Institute For Medical Research Methode et marqueur d'isolement de cellules souches humaines hematopoietiques multipotentes

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998007444A1 (fr) * 1996-08-16 1998-02-26 Biotransplant, Inc. ANTICORPS LO-CD2a ET SON UTILISATION POUR INHIBER L'ACTIVATION ET LA PROLIFERATION DE CELLULES T
WO2001025398A2 (fr) * 1999-10-01 2001-04-12 Biotransplant Incorporated Technique permettant d'induire une tolerance fonctionnelle a des produits de transfert genique
WO2001030369A1 (fr) * 1999-10-22 2001-05-03 Biotransplant, Inc. Procede d'induction d'une tolerance immunologique pour des greffons heterologues
WO2001087310A1 (fr) * 2000-05-18 2001-11-22 Biotransplant, Inc. Procede de reduction de la reponse anticorps contre des xenogreffes
WO2002033043A2 (fr) * 2000-10-18 2002-04-25 Coriell Institute For Medical Research Methode et marqueur d'isolement de cellules souches humaines hematopoietiques multipotentes

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BUHLER L. ET AL: "High-dose porcine hematopoietic cell transplantation combined with CD40 ligand blockade in baboons prevents an induced anti-pig humoral response", TRANSPLANTATION, vol. 69, no. 11, 15 June 2000 (2000-06-15), pages 2296 - 2304, XP002978334 *
BUHLER L. ET AL: "Pig hematopoietic cell chimerism in baboons conditioned with a nonmyeloablative regimen and CD154 blockade", TRANSPLANTATION, vol. 73, no. 1, 15 January 2002 (2002-01-15), pages 12 - 22, XP002978708 *
GIOVINO MA ET AL: "Porcine hematopoiesis on primate stroma in long-term cultures: enhanced growth with neutralizing tumor necrosis factor-alpha and tumor growth factor-beta antibodies", TRANSPLANTATION, vol. 73, no. 5, 15 March 2002 (2002-03-15), pages 723 - 731, XP002978373 *

Also Published As

Publication number Publication date
AU2003245752A8 (en) 2004-01-19
WO2004002425A2 (fr) 2004-01-08
AU2003245752A1 (en) 2004-01-19

Similar Documents

Publication Publication Date Title
Carlson et al. Platelet-rich plasma: clinical applications in dentistry
Kitoh et al. Transplantation of marrow-derived mesenchymal stem cells and platelet-rich plasma during distraction osteogenesis—a preliminary result of three cases
Kawasumi et al. The effect of the platelet concentration in platelet-rich plasma gel on the regeneration of bone
Connolly Injectable bone marrow preparations to stimulate osteogenic repair
AU697761B2 (en) Decontaminating blood components with 8-methoxypsoralen
Smrke et al. Treatment of bone defects—allogenic platelet gel and autologous bone technique
DE60038884D1 (en) Autologes thrombin
WO2004094619A3 (fr) Cellules souches hematopoietiques traitees par fucosylation in vitro et procedes pour les utiliser
DE69922362D1 (de) Methode zur präparation eines diafiltrierten stabilen blutproduktes
GB0001309D0 (en) Valve arrangement
De Fabritiis et al. Elimination of clonogenic Burkitt's lymphoma cells from human bone marrow using 4-hydroperoxycyclophosphamide in combination with monoclonal antibodies and complement
WO1999003976A3 (fr) Traitement des leucocytes, compositions leucocytaires, et leur procede d'utilisation
EP1491093A3 (fr) Cellules souches adultes totipotentes, sources de ces cellules, procedes d'obtention et de maintien de ces dernieres, procedes de differentiation de ces cellules, procedes d'utilisation correspondants et cellules derivees des cellules susmentionnees
AU5459199A (en) Apparatus and method of preparation of stable, long term thrombin from plasma and thrombin formed thereby
WO1999046366A8 (fr) Utilisations de cellules souches humaines mesenchymateuses non autologues
WO2000040269A3 (fr) Compositions pharmaceutiques destinees au traitement des tissus malades
NO20060498L (no) Metode for a promotere benvekst
IL144523A0 (en) Method and compositions for healing and repair of articular cartilage
HUS1900041I1 (hu) Treoszulfán alkalmazása betegek csontvelõ- és vér õssejt-transzplantáció elõtti kondicionálására
EP0953351A3 (fr) Médicaments contenant, comme ingrédient principal, des cellules CD4+ activées par un allogène et leur procédé de préparation
ATE442434T1 (de) Verfahren zur unterdrückung einer immunsystemreaktion gegen gewebe- oder zelltransplantate
WO2001094586A3 (fr) Anticorps non agonistiques diriges contre gp 39 humaine, compositions les contenant et leur utilisation therapeutique
EP1890713B1 (fr) Composition osteoblastique a base de fibrine melangee semi-solidifiee utilisee pour produire une agglutination en cas de fracture osseuse et son procede de production
Couban et al. The source of cells for allografting
MXPA02011592A (es) Composiciones de celulas dendriticas circulantes, humanas y metodos.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP